Company news
NeoGenomics, Inc. news in 2022
NeoGenomics, Inc.'s news releases, calls and decks from 2022, newest first.
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 4, 2022
NeoGenomics Announces Chief Financial Officer Transition
December 4, 2022
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
November 20, 2022
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
November 17, 2022
NeoGenomics Reports Third Quarter 2022 Results
November 7, 2022
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
November 6, 2022
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
October 27, 2022
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
October 12, 2022
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
September 6, 2022
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
August 8, 2022
NeoGenomics Announces Chief Executive Officer Appointment
July 20, 2022
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
July 14, 2022
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
June 20, 2022
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
June 2, 2022
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
June 2, 2022
NeoGenomics Appoints Lynn Tetrault Interim CEO
May 15, 2022
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
May 9, 2022
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
May 8, 2022
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
May 4, 2022
NeoGenomics Reports Revenue of $117 Million in the First Quarter
April 26, 2022
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
April 24, 2022
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
April 10, 2022
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
April 10, 2022
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
April 7, 2022
NeoGenomics Announces CEO Departure and Initiates CEO Search
March 27, 2022
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
March 16, 2022
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
February 22, 2022
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
February 13, 2022
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
February 10, 2022
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
February 7, 2022
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
February 1, 2022
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
January 23, 2022
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 10, 2022